

# **Patient group direction for the supply of a fluconazole 150mg capsule and clotrimazole 1% cream by community pharmacists for the first line management of vulvo-vaginal candidiasis**

## **Documentation details**

Reference no: PGD05

Version no: 2.1

Valid from: April 2023

Review date: December 2024

Expiry date: March 2025

## **Change history**

<b>Version number</b>	<b>Date</b>	<b>Details</b>
1	11 Jan 2022	New PGD
1.1	4 Feb 2022	Clarified duration of treatment with clotrimazole cream
2		Transfer to ICB stationery Renumber to PGD05 Review of PGD
2.1	29 April 2024	Added patient advice regarding fluconazole and pregnancy in line with updated SmPC

## Patient group direction development

Date template comes into effect: April 2023

Version no: 2

Valid from: April 2023

Review date: December 2024

Expiry date: March 2025

## Patient group direction working group

This patient group direction (PGD) was developed by a working group involving pharmacists from NHS Cornwall and Isles of Scilly integrated care board (CIOS ICB), GP clinical leads from CIOS ICB and microbiology. Adapted from the SPS template.

Name and role	Job title	Organisation
Chris Burgin Pharmacist and lead author	Pharmaceutical advisor	Cornwall and Isles of Scilly ICB
Anne Jones Pharmacist	Pharmaceutical advisor	Cornwall and Isles of Scilly ICB
Medicines optimisation programme board (MOPB), reviewers, February 2023		
Dr Jim Huddy, GP	General practitioner	Cornwall and Isles of Scilly ICB
Mike Wilcock, pharmacist	Head of prescribing support unit	Royal Cornwall Hospitals NHS Trust (RCHT) and Cornwall and Isles of Scilly ICB
Philip Yelling	Consultant	Cornwall and Isles of Scilly Local Pharmaceutical Committee

## Organisational authorisations



The PGD is not legally valid until it has had the relevant organisational authorisation.

It is the responsibility of the organisation that has legal authority to authorise the PGD, to ensure that all legal and governance requirements are met. The authorising body accepts governance responsibility for the appropriate use of the PGD.

CIOS ICB authorises this PGD for use by the services or providers listed below:

**Authorised for use by the following organisation and/or services:** Community pharmacies contracted to provide the CIOS ICB community pharmacy PGD service for minor ailments.

**Limitations to authorisation:** None.

Approved by	Name	Date of email approval
CIOS ICB interim head of prescribing and medicines optimisation	Marco Motta 	28 February 2023
CIOS ICB chief medical officer	Chris Reid	Approved by email 26 February 2023
CIOS ICB chief nursing officer	Susan Bracefield 	7 March 2023

Local enquiries regarding the use of this PGD may be directed to [ciosicb.prescribing@nhs.net](mailto:ciosicb.prescribing@nhs.net)

Individual registered health professionals must be authorised by name to work to this PGD. This should be recorded on the authorisation sheet at the end of this document.

## Characteristics of staff

### Qualifications and professional registration

Registered professional with one of the following bodies:

- Pharmacists registered with the General Pharmaceutical Council (GPhC)

### Initial training

- Must be authorised by name as an approved practitioner under the current terms of this PGD before working to it
- Has undertaken appropriate training and been assessed and declared competent to carry out clinical assessment of patient leading to diagnosis that requires treatment according to the indications listed in this PGD
- Must be competent in the use of PGDs (see [NICE competency framework](#) for health professionals using PGDs)
- Must have access to the PGD and associated online resources

### Competency assessment

All pharmacists operating under this PGD are required to complete a [declaration of competence for minor ailments](#) via the Centre Pharmacy Postgraduate Education (CPPE) website and complete the declaration of competence on PharmOutcomes.

Staff operating under this PGD are encouraged to attend specific commissioning organised training events on minor ailments and complete the CPPE [common clinical conditions and minor ailments](#) and [e-assessment](#).

Individuals operating under this PGD are personally responsible for ensuring they remain up to date with the use of all medicines included in the PGD.

### Ongoing training and competency

Practitioners must ensure they are up to date with relevant issues and clinical skills relating to the management of vulvo-vaginal candidiasis, with evidence of appropriate continued professional development (CPD).

Pharmacists will be required to complete an annual [declaration of competence](#) via the CPPE website and PharmOutcomes.

The decision to supply any medication rests with the individual registered health professional who must abide by the PGD and any associated organisation policies.

## Clinical condition or situation to which this PGD applies

**Condition or situation:** First line treatment of vulvo-vaginal candidiasis as per [NICE guidelines](#), including topical imidazole where there are vulval symptoms.

### Criteria for inclusion

- An individual with reported symptoms including:
  - Vulval or vaginal itching (often the defining symptom)
  - Vulval or vaginal soreness and irritation
  - Vaginal discharge (usually white, 'cheese-like', and non-malodorous)
  - Superficial dyspareunia
  - Dysuria (pain or discomfort during urination)

### Criteria for exclusion

- Women aged under 16 or over 60 years
- Known or suspected pregnancy
- Individuals with 4 or more treated episodes of candidiasis in the preceding 12 months, or 2 or more treated episode in the preceding 6 months.
- Individuals with genital sores or ulcers suggestive of other infections or conditions
- Individuals with pelvic pain where pelvic inflammatory disease (PID) has not been excluded
- Individuals with abnormal vaginal bleeding where cause has not been identified
- Recurrent or unresolved symptoms of candidiasis within 4 weeks of being treated
- Individuals who are immunosuppressed and may require further assessment and systemic treatment
- Individuals with acute porphyria
- Past or current history of cardiac rhythm disturbance
- Patients with hypokalemia and advanced cardiac failure
- Known liver impairment
- Doubt over diagnosis
- Individual is taking interacting medicines. Check appendix 1 of current print edition of British National Formulary (BNF) for full list, or [online](#)

- Individuals with a known allergy to fluconazole or to related azole compounds or any of the constituents found within the formulation
- Individuals with a known allergy to clotrimazole or any other imidazole antifungal, or to any of the constituents found within the formulation

### **Cautions including any relevant action to be taken**

Discuss with appropriate medical or independent non-medical prescriber any medical condition or medication of which the pharmacist is unsure or uncertain.

### **Action to be taken if the patient is excluded**

- Explain the reasons for exclusion to the individual
- Record reasons for exclusion and any action(s) taken
- Advise patient on alternative treatment
- Refer to a prescriber if appropriate (for example GP or NHS 111 or out of hours (OOH) services)
- Give safety-netting advice

### **Action to be taken if the patient declines treatment**

- Ensure the individual is aware of the need for treatment and the potential consequences of not receiving treatment
- Document the reasons for declining, advice given and the decision reached
- Advise patient on alternative treatment if appropriate
- Refer to a prescriber if appropriate
- Give safety-netting advice

### **Arrangements for referral for medical advice**

Advise people with vulvo-vaginal candidiasis to seek medical help if symptoms worsen rapidly significantly at any time, or symptoms have not improved after completing a course of treatment.

## **Description of treatment – fluconazole 150mg capsule**

### **Name, strength and formulation of drug**

Fluconazole 150mg capsule

### **Legal category**

Prescription only medicine (POM)

### **Route and method of administration**

Oral

### **Indicate any off-label use (if relevant)**

Not applicable

### **Dose and frequency of administration**

Single 150mg dose

### **Duration of treatment**

1 dose

### Quantity to be supplied

1 capsule

### Storage

Stock must be stored in conditions in line with the [summary of product characteristics \(SPC\)](#)

### Drug interactions

- Fluconazole has a number of drug-drug interactions which may be clinically significant and all concurrent medications should be reviewed for interactions
- Where a significant interaction is identified which may require dosage amendment or additional monitoring refer to appropriate medical or independent non-medical prescriber
- A detailed list of all drug interactions is available in the [BNF online](#) or the product SmPC, which is available from the electronic medicines compendium (EMC) website [www.medicines.org.uk](http://www.medicines.org.uk)

### Increased risk of adverse reactions

A detailed list of adverse reactions is available in the SmPC, which is available from the EMC website [www.medicines.org.uk](http://www.medicines.org.uk) and BNF [www.bnf.org](http://www.bnf.org)

### Identification and management of adverse reactions

- The following side effects are commonly reported with fluconazole (but may not reflect all reported side effects): headache, abdominal pain, diarrhoea, nausea, vomiting, rash
- This list is not exhaustive; refer to BNF or SPC for full details

## Description of treatment – clotrimazole 1% cream

### Name, strength and formulation of drug

Clotrimazole 1% cream

### Legal category

Pharmacy (P) medicine

### Route and method of administration

Topical

### Indicate any off-label use (if relevant)

Not applicable

### Dose and frequency of administration

Apply two or three times a day

### Duration of treatment

To be applied as needed for a maximum of 7 days

### Quantity to be supplied

20g tube

### Storage

Stock must be stored in conditions in line with the [summary of product characteristics \(SPC\)](#)

### Drug interactions

- All concurrent medications should be reviewed for interactions

- Where a significant interaction is identified which may require dosage amendment or additional monitoring refer to appropriate medical or independent non-medical prescriber
- A detailed list of all drug interactions is available in the [BNF online](#) or the product SmPC, which is available from the EMC website [www.medicines.org.uk](http://www.medicines.org.uk)

### Increased risk of adverse reactions

A detailed list of adverse reactions is available in the SmPC, which is available from the EMC website [www.medicines.org.uk](http://www.medicines.org.uk) and BNF [www.bnf.org](http://www.bnf.org)

### Identification and management of adverse reactions

- The following side effects are commonly reported with clotrimazole (but may not reflect all reported side effects): abdominal pain, genital peeling or bleeding, pruritus, rash, oedema, erythema and discomfort or burning
- This list is not exhaustive; refer to BNF or SPC for full details

### Management of and reporting procedure for adverse reactions

- Healthcare professionals and patients or carers are encouraged to report suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the [Yellow Card reporting scheme](#)
- Record all adverse drug reactions (ADRs) in the patient's medical record (and inform the patient's GP)
- Report via organisation incident policy

### Written information to be given to patient or carer

- The marketing authorisation holders' patient information leaflets provided with the products if treatment is to be supplied and advise patient to read the leaflet
- Patient information on vulvo-vaginal candidiasis can be viewed and printed from the [NHS website](#) and [patient.info](http://patient.info)

### Patient advice and follow up treatment

- Provide advice on using the medication:
  - Advise that clotrimazole cream may cause damage to latex condoms; the effectiveness of such contraceptives may be reduced, it is advised to use alternative precautions during and for at least 5 days after using this product
- Provide advice on measures to relieve symptoms:
  - Use simple emollients as a soap substitute to wash and/or moisturize the vulval area
  - Avoid contact with potentially irritant soap, shampoo, bubble bath, or shower gels, wipes, and daily or intermenstrual 'feminine hygiene' pad products
  - Avoid vaginal douching
  - Avoid wearing tight-fitting and/or non-absorbent clothing, which may irritate the area
  - Avoid use of complementary therapies such as application of yoghurt, topical or oral probiotics, and tea tree or other essential oils
- The patient should be advised to seek medical advice in the event of an adverse reaction
- If after 7 days symptoms persist or worsen advise the patient to contact their GP
- Patients planning on becoming pregnant should be advised to wait at least a week after stopping fluconazole before undertaking unprotected sexual intercourse, due to a very low increased risk of miscarriage.

### Records

- Completion of PGD checklist on PharmOutcomes.
- Completion of patient medication record.

- Label the pack being supplied appropriately:
  - Dose, form and route of supply or administration
  - Quantity supplied or administered
  - Supplied via PGD
- Record details of any adverse drug reactions and actions taken
- Referral arrangements (including self-care)
- Batch number and expiry date (if applicable)
- Completion of consent form and completion of the audit claim on PharmOutcomes
- Records should be signed and dated (or a password controlled e-records).
- All records should be clear, legible and contemporaneous
- A record of all individuals receiving treatment under this PGD should also be kept for audit purposes in accordance with local policy

### Audit trail

- PMR entry
- Patient's GP should be notified using the notification form on PharmOutcomes within 48 hours of supply for inclusion in the patients notes

### Key references

- [NICE CKS – Candida – female genital](#)
- [NHS UK – Thrush in man and women](#)
- [CIOS ICB management of infection guidelines](#)
- [Patient.info – vaginal thrush](#)
- [BNF – fluconazole monograph](#)
- [BNF – clotrimazole monograph](#)
- [Electronic Medicines Compendium \(EMC\)](#)
- [NICE PGD medicines practice guideline \[MPG2\]](#)
- [Specialist Pharmacy website](#)

### Registered health professional authorisation sheet

**PGD:** Patient group direction for the supply of a fluconazole 150mg capsule and clotrimazole 1% cream by community pharmacists for the first line management of vulvo-vaginal candidiasis

**Valid from:** April 2023

**Expiry:** March 2025

Before signing this PGD, check that the document has had the necessary authorisations above. Without these, this PGD is not lawfully valid.

### Authorisation

By signing this patient group direction, you are indicating that you agree to its contents and that you will work within it.

Patient group directions do not remove inherent professional obligations or accountability.

It is the responsibility of each professional to practise only within the bounds of their own competence and professional code of conduct.



I confirm that I have read and understood the content of this PGD and that I am willing and competent to work to it within my professional code of conduct.

Name	Designation	Signature	Date

This authorisation sheet should be retained to serve as a record of those registered health professionals authorised to work under this PGD.